CAR-T for Pediatric B-ALL: Expert Tips
Show notes
In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and relapse risk.
The conversation highlights key questions surrounding the role of allo-HSCT in the CAR T era. Prof Baruchel also explores emerging approaches designed to improve outcomes, including dual-targeted CARs, strategies to enhance cellular persistence.
Listen now for insights into how fourth-generation CAR constructs that modify the tumour microenvironment, and in vivo CAR therapies may further transform the treatment of pediatric B-ALL.
Guests: Prof André Baruchel
Affiliation: Professor of Pediatrics, Université Paris-Cité; former Head of the Pediatric Hematology Immunology Department, Hôpital Robert-Debré, Paris
Host: Leah DeLeon
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe